Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study.
Cost-effectiveness
Economic evaluation
HEALing Communities Study
Helping to end addiction long term
Opioid use disorder
Overdose
Simulation
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
17
08
2020
revised:
17
09
2020
accepted:
18
09
2020
pubmed:
6
11
2020
medline:
10
4
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
The HEALing Communities Study (HCS) is designed to implement and evaluate the Communities That HEAL (CTH) intervention, a conceptually driven framework to assist communities in selecting and adopting evidence-based practices to reduce opioid overdose deaths. The goal of the HCS is to produce generalizable information for policy makers and community stakeholders seeking to implement CTH or a similar community intervention. To support this objective, one aim of the HCS is a health economics study (HES), the results of which will inform decisions around fiscal feasibility and sustainability relevant to other community settings. The HES is integrated into the HCS design: an unblinded, multisite, parallel arm, cluster randomized, wait list-controlled trial of the CTH intervention implemented in 67 communities in four U.S. states: Kentucky, Massachusetts, New York, and Ohio. The objectives of the HES are to estimate the economic costs to communities of implementing and sustaining CTH; estimate broader societal costs associated with CTH; estimate the cost-effectiveness of CTH for overdose deaths avoided; and use simulation modeling to evaluate the short- and long-term health and economic impact of CTH, including future overdose deaths avoided and quality-adjusted life years saved, and to develop a simulation policy tool for communities that seek to implement CTH or a similar community intervention. The HCS offers an unprecedented opportunity to conduct health economics research on solutions to the opioid crisis and to increase understanding of the impact and value of complex, community-level interventions.
Sections du résumé
BACKGROUND
The HEALing Communities Study (HCS) is designed to implement and evaluate the Communities That HEAL (CTH) intervention, a conceptually driven framework to assist communities in selecting and adopting evidence-based practices to reduce opioid overdose deaths. The goal of the HCS is to produce generalizable information for policy makers and community stakeholders seeking to implement CTH or a similar community intervention. To support this objective, one aim of the HCS is a health economics study (HES), the results of which will inform decisions around fiscal feasibility and sustainability relevant to other community settings.
METHODS
The HES is integrated into the HCS design: an unblinded, multisite, parallel arm, cluster randomized, wait list-controlled trial of the CTH intervention implemented in 67 communities in four U.S. states: Kentucky, Massachusetts, New York, and Ohio. The objectives of the HES are to estimate the economic costs to communities of implementing and sustaining CTH; estimate broader societal costs associated with CTH; estimate the cost-effectiveness of CTH for overdose deaths avoided; and use simulation modeling to evaluate the short- and long-term health and economic impact of CTH, including future overdose deaths avoided and quality-adjusted life years saved, and to develop a simulation policy tool for communities that seek to implement CTH or a similar community intervention.
DISCUSSION
The HCS offers an unprecedented opportunity to conduct health economics research on solutions to the opioid crisis and to increase understanding of the impact and value of complex, community-level interventions.
Identifiants
pubmed: 33152672
pii: S0376-8716(20)30501-9
doi: 10.1016/j.drugalcdep.2020.108336
pmc: PMC7532345
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108336Subventions
Organisme : NIDA NIH HHS
ID : UM1 DA049415
Pays : United States
Organisme : NIDA NIH HHS
ID : UM1 DA049417
Pays : United States
Organisme : NINR NIH HHS
ID : L30 NR018771
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NIDA NIH HHS
ID : K01 DA051348
Pays : United States
Organisme : NIDA NIH HHS
ID : UM1 DA049394
Pays : United States
Organisme : NIDA NIH HHS
ID : UM1 DA049412
Pays : United States
Organisme : NIDA NIH HHS
ID : UM1 DA049406
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR002602
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Am J Manag Care. 2019 Jul;25(13 Suppl):S243-S249
pubmed: 31361426
Drug Alcohol Depend. 2016 Dec 01;169:117-127
pubmed: 27810654
JAMA Netw Open. 2019 Feb 1;2(2):e187621
pubmed: 30707224
Eur J Health Econ. 2020 Jul;21(5):717-728
pubmed: 32108274
Am J Public Health. 2015 Aug;105(8):e55-63
pubmed: 26066931
Pharmacoeconomics. 2014 Dec;32(12):1157-70
pubmed: 25069632
J Manag Care Spec Pharm. 2019 Jan;25(1):18-27
pubmed: 30589633
Pharmacoeconomics. 2016 Sep;34(9):863-87
pubmed: 27002518
J Addict Med. 2019 Jul/Aug;13(4):251-252
pubmed: 30633046
Prev Sci. 2012 Apr;13(2):150-61
pubmed: 22108900
N Engl J Med. 2014 Aug 28;371(9):796-7
pubmed: 25162885
Int J Drug Policy. 2019 Oct;72:160-168
pubmed: 31085063
Psychiatr Serv. 2019 Dec 1;70(12):1082-1087
pubmed: 31451063
J Subst Abuse Treat. 2017 Oct;81:25-34
pubmed: 28847452
JAMA. 2018 Jun 26;319(24):2473-2474
pubmed: 29800152
J Subst Abuse Treat. 2020 Aug;115:108042
pubmed: 32600623
Ann Intern Med. 2019 Jan 15;170(2):90-98
pubmed: 30557443
Addiction. 2017 Aug;112(8):1440-1450
pubmed: 28239984
Int J Drug Policy. 2019 Sep;71:118-124
pubmed: 31330267
Drug Alcohol Depend. 2020 Dec 1;217:108335
pubmed: 33248391
Ann Intern Med. 2018 Jan 2;168(1):10-19
pubmed: 29159398
Am J Public Health. 2018 May;108(5):659-665
pubmed: 29565666
Med Care. 2016 Oct;54(10):901-6
pubmed: 27623005
Med Care. 2019 Jul;57(7):494-497
pubmed: 30844906
Drug Alcohol Depend. 2020 Dec 1;217:108328
pubmed: 33091844
JAMA Netw Open. 2018 Sep 7;1(5):e182908
pubmed: 30646184
Health Econ. 2003 May;12(5):377-92
pubmed: 12720255
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297
pubmed: 32191688
J Subst Abuse Treat. 2018 Nov;94:81-90
pubmed: 30243422
Pain Med. 2013 Oct;14(10):1534-47
pubmed: 23841538
J Exp Criminol. 2015 Jun 1;11(2):165-192
pubmed: 26213527
Ann Intern Med. 2013 Jan 1;158(1):1-9
pubmed: 23277895
Health Econ. 1997 May-Jun;6(3):217-27
pubmed: 9226140
Drug Alcohol Depend. 2020 Dec 1;217:108325
pubmed: 33091842
Lancet Gastroenterol Hepatol. 2018 Dec;3(12):819
pubmed: 30507463
Value Health. 2020 Aug;23(8):1096-1108
pubmed: 32828223
Drug Alcohol Depend. 2020 Dec 1;217:108338
pubmed: 33152673
Addiction. 2017 Nov;112(11):2002-2010
pubmed: 28815789
Drug Alcohol Depend. 2020 Dec 1;217:108330
pubmed: 33086156
JAMA. 2000 Oct 4;284(13):1689-95
pubmed: 11015800
Int J Drug Policy. 2021 Feb;88:102726
pubmed: 32359858
Addiction. 2015 Dec;110(12):1975-84
pubmed: 26212260
Int J Drug Policy. 2020 Jan;75:102536
pubmed: 31439388
Drug Alcohol Depend. 2020 Dec 1;217:108326
pubmed: 33059200
Med Decis Making. 2012 Sep-Oct;32(5):733-43
pubmed: 22990088